ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial.
Louise ChinaSimon S SkeneKate BennettZainib ShabirRoseanna HamiltonScott BevanTorsten ChandlerAlexander A MainiNatalia BecaresDerek GilroyEwan H ForrestAlastair O'BrienPublished in: BMJ open (2018)
Research ethics approval was given by the London-Brent research ethics committee (ref: 15/LO/0104). The clinical trials authorisation was issued by the medicines and healthcare products regulatory agency (ref: 20363/0350/001-0001). The trial is registered with the European Medicines Agency (EudraCT 2014-002300-24) and has been adopted by the National Institute for Health Research (ISRCTN 14174793). This manuscript refers to version 6.0 of the protocol. Results will be disseminated through peer-reviewed journals and international conferences. Recruitment of the first participant occurred on 25 January 2016.
Keyphrases
- liver failure
- clinical trial
- study protocol
- drug administration
- healthcare
- public health
- hepatitis b virus
- big data
- phase ii
- randomized controlled trial
- phase iii
- global health
- open label
- transcription factor
- quality improvement
- psychometric properties
- machine learning
- double blind
- artificial intelligence
- health information
- meta analyses
- social media